<DOC>
	<DOCNO>NCT00020839</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . It yet know chemotherapy effective without radiation therapy treat brain metastasis . PURPOSE : Randomized phase III trial compare effectiveness chemotherapy without radiation therapy brain treat patient stage IV melanoma asymptomatic brain metastasis .</brief_summary>
	<brief_title>Temozolomide With Without Radiation Therapy Brain Treating Patients With Stage IV Melanoma That Is Metastatic Brain</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy temozolomide without radiotherapy term overall survival patient stage IV melanoma asymptomatic brain metastasis . - Compare time appearance neurological symptom patient treat regimen . - Compare progression-free survival patient treat regimen . - Compare quality life quality-adjusted survival patient treat regimen . - Compare toxicity regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify accord LDH level ( less 225 U/L v 225 U/L ) , concurrent metastasis ( visceral v soft tissue ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral temozolomide daily day 1-5 . Treatment continue every 4 week maximum 1 year absence disease progression unacceptable toxicity . - Arm II : Patients receive temozolomide arm I whole brain radiotherapy day 8-12 15-19 first course chemotherapy . Quality life assess begin course every 4 week completion study drug . Patients follow every 4 week . PROJECTED ACCRUAL : A total 250 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable metastatic melanoma Must asymptomatic brain metastasis amenable surgery stereotactic radiosurgery ( gamma knife , Linac ) Must concurrent visceral/soft tissue metastasis At least 1 site measurable disease ( necessarily brain metastasis ) Documented evidence disease progression define 1 follow condition : More 25 % increase size least 1 measurable lesion Appearance new lesion A significant increase size nonmeasurable disease No neurological symptom , include sign elevate intracranial pressure PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT SGPT less 3 time ULN Alkaline phosphatase less 3 time ULN Renal : Urea le 1.5 time ULN Creatinine less 1.5 time ULN Other : No frequent vomit medical condition ( e.g. , partial bowel obstruction ) would interfere oral medication intake No prior concurrent malignancy except surgically cure carcinoma situ cervix basal cell squamous cell skin cancer No uncontrolled infection HIV negative No AIDSrelated illness Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No psychological , familial , sociological , geographical condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Prior cytokine via isolated limb perfusion localregional melanoma allow No prior cytokine metastatic melanoma No concurrent colonystimulating factor , include epoetin alfa filgrastim ( GCSF ) No concurrent immunologic biologic therapy Chemotherapy : Prior chemotherapy via isolated limb perfusion localregional melanoma allow No prior chemotherapy metastatic melanoma No concurrent chemotherapy Endocrine therapy : Concurrent corticosteroid allow radiotherapy ( arm II ) No concurrent hormonal therapy Radiotherapy : See Disease Characteristics No concurrent radiotherapy Surgery : See Disease Characteristics Recovered effect prior major surgery Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>stage IV melanoma</keyword>
	<keyword>recurrent melanoma</keyword>
	<keyword>tumor metastatic brain</keyword>
</DOC>